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Abstract: Until the 1970s, infectious disease training in most medical schools was limited to those 
diseases common in the area of instruction. Those wishing to explore a more globalised curriculum 
were encouraged to undertake specialist postgraduate training at schools or institutes of tropical 
medicine. However, the increase in global trade and travel from the 1970s onward led to dramatic 
changes in the likelihood of returning travellers and new immigrants presenting with tropical 
infections in temperate regions. Furthermore, population growth and the changing relationships 
between animals, the environment, and man in agriculture accentuated the importance of a wider 
understanding of emerging infectious diseases, zoonotic diseases and parasitic infections. These 
epidemiological facts were not adequately reflected in the medical literature or medical curriculum 
at the time. The orientation on tropical infections needed specialised attention, including instruction 
on diagnosis and treatment of such infections. We describe key global health events and how the 
changing field of global medicine, from the 1970s to early 2000, impacted on medical education and 
research. We describe the impact of global health changes in the Tasmanian context, a temperate 
island state of Australia. We retrospectively analysed data of patients diagnosed with parasites and 
present a list of endemic and non-endemic parasites reported during this period. Finally, we reflect 
on the new approaches to the changing needs of global health and challenges that medical 
programmes, learners and educators face today. 
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1. Introduction 
In 1964 and based on concerns regarding tropical disease in temperate climates, Dr. Kevin Cahill 
published a series of articles in The New York State Journal of Medicine. He foresaw that inexpensive 
boat travel and the shortening transit times by air travel posed a potential infection hazard [1]. By 
1974, Woodruff in the preface to his book stated that “Medicine in the tropics is of great importance 
to all practitioners be they working in temperate or tropical regions” [2]. He had already noted that 
through travel “even in temperate regions, a significant proportion of the community has now been 
exposed to disease in tropical and subtropical regions” [2]. What he said then is even more important 
now with more global connections involving travel and trade, changes in climate, and the 
environment and human spread into previously uninhabited regions. These factors have led to the 
possibility of diseases with short incubation periods being brought to countries where they have not 
been seen before or have been exceedingly rare. Diseases with long and silent incubation periods 
present the most difficult diagnostic and public health problems. This, has led to growing clinical 
needs and development of medical practitioners, public health and health professionals with an 
understanding of these diseases, working at the local, regional, national, and global level. For those 
teaching and developing medical curricula these diseases present many challenges and have become 
more complex due to the changing focus of healthcare systems, globalisation, cultural and societal 
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factors, and technology. Despite international communications on medical education to address these 
needs, medical practice remains distinctly different among countries [3]. 
2. Time Line of Selected Global Health Events 
Why were the 1970s significant for changes in global medicine? The 1970s was a period when 
the post-World War II economic expansion and economic boom was drawing to an end and the 1973–
1975 recession loomed [4,5]. The economic crisis also affected the approach to the control of disease 
and much of the work in the field reflected the long-term instability and economic difficulty. The 
range of effective drugs used for human and animal treatment expanded rapidly. However, the 
treatment was not always in parallel with investigations of how these new drugs should be used to 
the best effect. Transport of livestock from country to country without an understanding of disease 
risks and intensive methods of animal management posed hazards to humans [2,6]. Preparing for 
reduced funding for medical and veterinary services to make further gains in health and wellbeing 
of humans and animals was not expected. Promoting efficient use of resources was common and a 
need for evaluation was obvious. 
The growing efficiency and reach of modern transport networks led to an emergence of new 
strains of familiar diseases, as well as completely new diseases. A consequence was the pressure on 
how to tackle them. It became apparent that there was strong correlation between antibiotic use in 
the treatment of humans and animals and antibiotic resistance in Gram-negative pathogens. The most 
prevalent Gram-negative pathogens at this time were Escherichia coli, Salmonella enterica, and Klebsiella 
pneumoniae [7]. Since then there has been an alarming increase in ‘superbugs’ and a decline in the 
development of new antibiotics to cope with the changing situation. Williamson et al. [8] recently 
highlighted the danger of drug resistance in Candida auris, carbapenemase-producing 
enterobacteriaceae, Methicillin-resistant Staphylococcus aureus (MRSA) and drug-resistant strains of 
typhoid and gonorrhoea. Infectious disease specialists note that the world has reached a crisis in the 
treatment of bacterial infections [9,10]. 
Between 1965 and 1970, the growth rate of the world’s population reached its peak, increasing 
by 2.1% per year on average [11]. There was a growing concern of the impact of this population 
growth on the interaction of humans and the environment and how this would affect tropical 
diseases. A combination of increased economic activity, human migration, tourism, and 
encroachment on new environmental niches contributed to the emergence of many zoonotic diseases. 
The first cases of naturally acquired Plasmodium knowlesi infection [12], the Marburg, Ebola, and Lassa 
fever viruses [13], and reports of Lyme disease [14] occurred during this period. The earliest reports 
of a syndrome later identified as HIV/AIDS appeared in the closing year of the 1970s [14]. 
The 1970s saw the rise of preventive medicine and the self-care movements [15]. In the early part 
of June 1972, the United Nations Conference on the Human Environment in Stockholm considered 
the need for “a common outlook and for common principles to inspire and guide the peoples of the 
world in the preservation and enhancement of the human environment” [16]. Following the 
Stockholm Declaration, global awareness of environmental issues increased dramatically. In 1992, 
the second United Nations Conference on Environment and Development (UNCED) in Rio de Janeiro 
represented a major milestone in the evolution of international environmental law [17]. Today, the 
Sustainable Goals (SDGs) of the United Nations and the Agenda 2030 reflect the spirit of these 
principles. 
The 1970s initiated great strides in global disease control. A successful example was the 
Onchocerciasis Control programme, which commenced in 1974 [18]. The serious health and 
socioeconomic repercussions of onchocerciasis and indications of possible control was a catalyst for 
a convening of a joint USAID/OCCGE/WHO technical meeting [18,19]. The participants included 
experts in a range of fields including public health, parasitology, epidemiology, entomology, 
ophthalmology, economics, sociology, and medical geography [18]. The programme brought relief 
to many communities and with great effort was sustained and continues today, despite difficult 
circumstances. This programme has become an example of effective public health management and 
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one of the largest intercountry undertakings implemented by the World Health Organization 
(WHO)[19,20]. 
The decade of the 1970s closed with the successful eradication of smallpox after a 14-year 
intensive programme [21] and the beginning of new global control programmes. There were specific 
efforts to increase efficiency and productivity of healthcare systems during the 1980s, including 
improvement in maternal and child health and a focus on HIV/AIDS, tuberculosis, and malaria in 
developing countries. In 1986, the Global Programme on AIDS (GPA) was launched by the World 
Health Organization  [22] followed by the Global Polio Eradication Initiative (GPEI) in 1988, which 
was led jointly by national governments, the WHO, Rotary International, the US Centers for Disease 
Control and Prevention (CDC), and UNICEF [22,23]. 
In 1992, the CDC launched the international campaign to eradicate Guinea worm disease and 
eliminate dracunculiasis [24]. The 1990s welcomed the evolution of large data-driven research and 
collaboration with the World Bank commissioned to publish the Global Burden of Disease study. 
Today this collaboration has over 1800 researchers and contributors from 127 countries [25]. Another 
significant global achievement at this time was the Global Initiative for Traditional Systems of Health 
created by the Pan American Health Organisation [26]. Today WHO continues to develop proactive 
policies and action plans to strengthen the role of traditional and complementary medicine (T&CM) 
in responding to health needs of populations. Unfortunately, it remains an ongoing challenge for 
countries trying to implement regulations and national laws for their use [26]. 
The next factor which influenced human health over these years, and more evident today, was 
climate change. Changing climate, spread of warmer conditions, and changing rainfall can increase 
the occurrence of tropical diseases such as malaria, dengue and schistosomiasis and potentially soil 
transmitted helminthiases by extending their distribution [27]. Changing climate, including 
pollution, exacerbates public health issues and economic stagnation due to parasitic diseases and 
these complexities have been highlighted by numerous authors [28–31]. Thus, Han et al. [32] stated 
that “Health organisations are growing more concerned that climate change will cause zoonotic 
diseases to become more prolific and widespread” and challenges are more difficult in predicting 
outbreaks caused by either novel pathogens or known pathogens in novel places. 
The continued pressure of economic development has increased the opportunity for pathogens 
(many previously unknown) with zoonotic potential to cross the species line. The world’s population 
has continued to grow from 3.7 billion in the 1970s to 7.7 billion in 2019 [33] and is projected to 
increase to 9.7 billion by 2050. Health professionals need to be aware of growth rates and mobility 
patterns across their regions [34]. Goldsmid [35] noted “that never before in the history of the human 
race, have so many people been able to travel so far so quickly and so cheaply”—and this is even 
truer today! 
A review of the literature estimates the number of people that acquire an infectious disease 
during or as a result of travel ranges from 6% to 87% [36]. These figures may change as current 
projections suggest the annual number of international travellers will reach 1.8 billion by 2030 [36]. 
International tourism in Australia for example has grown significantly in the past two decades. The 
number of short-term overseas visitor arrivals rose from 2.5 million in 1992 to 9.3 million in 2018–
2019, the highest year on record [37]. Outbound international trips have nearly doubled in the past 
decade. The scale and speed of contemporary international travel means an increasing possibility of 
travellers being exposed to unfamiliar infections. 
Accurate data of the proportion of people who acquire an illness overseas are difficult to 
calculate as exposure is dependent on the destination, baseline medical history, and also planned 
activities [38]. In recent years research in travel medicine has grown. There are tropical medicine 
surveillance networks, such as the GeoSentinel surveillance network composed of International 
Society of Travel Medicine (ISTM) travel and tropical medicine clinics that collect post-travel illness 
surveillance data [39,40], but there are limitations. Therefore, physicians need to be familiar with 
destination-specific disease risks, travel and routine vaccines, and chemoprophylaxis regimens. 
Reviews of current evidence in the discipline are readily available [41]. 
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A major area of medical relevance in the fields of tropical travel, migrant and refugee medicine 
is parasitic infections. The estimates of the prevalence and incidence of neglected tropical diseases 
and malaria from the Global Burden of Disease Study 2017 [42] are thought provoking. While some 
parasitic diseases such as falciparum malaria and human African trypanosomiasis (East African 
variety) cause acute infections with a high mortality, most parasitic infections are chronic infections. 
An example is cysticercosis [43–45] which is increasingly recorded in non-endemic regions around 
the world [43]. 
3. Historical Overview of Tasmania and Parasites of Medical Importance 
Historically, nearly all of the infectious diseases seen in Australia, and especially Tasmania, have 
been imported since European/Asian settlement of the continent [46] and many of the commoner 
infections then became endemic as the population grew. Tasmania has a long history associated with 
imported infections, starting with the first settlement by Europeans (especially the convicts) and 
continuing from there. Tasmania provides a strong case against a parochial approach to medicine – 
especially in the changing world today. It is a good model for study in relation to imported infections 
and the relevance of travel in this regard. The reasons are: 
(1) Tasmania is a small relatively isolated island, protected by surrounding water. 
(2) Tasmania has a temperate climate with a high standard of living and with good health services. 
(3) Tasmania has a small resident population and consequently has fewer overseas travellers or 
returning travellers. 
(4) Tasmania has few direct overseas connections and fewer overseas visitors than the more 
populous and easily accessible mainland states of Australia. 
The question thus arises—How big a range of endemic and ‘exotic’ imported infections has been 
diagnosed in humans in Tasmania over recent years? A retrospective analysis of recorded cases was 
completed and is reported below. Helminth infections are summarised in Table 1 and other key 
parasites diagnosed in Tasmania in Table 2. 
Table 1. Helminth infections diagnosed in Tasmania: 
Trematodes: Cestodes: Nematodes: 
Echinostoma sp. ** Echinococcus granulosis *** Ancylostoma duodenale ** 
Fasciola hepatica ** Hymenolepis nana *** Ascaris lumbricoides *** 
Opisthorchis 





Cutaneous larva migrans ** 
Schistosoma 
mansoni ** 
 Enterobius vermicularis * 
  Eucoleus aerophilus (Capilalria aerophila) * 
Haycocknema perplexum ** 
  Loa loa ** 
  Necator americanus ** 
  Strongyloides stercoralis ** 
  Toxocara spp * 
  Trichinella pseudospiralis * 
  Trichuris trichiura *** 
  Trichostrongylus spp ** 
  Wuchereria bancrofti lymphatic filariasis and 
tropical pulmonary eosinophilia ** 
Key to coding: Endemic cases *, Imported cases **, Endemic and imported cases ***. 
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Table 2. Protozoa and Arthropoda diagnosed in Tasmania. 
Protozoa Arthropoda—Insecta: Arthropoda—Acarina 
Chilomastix mesnili *** Cordylobia anthropophaga ** Sarcoptes scabiei * 
Cryptosporidium spp * Dermatobia hominis ** Ixodid ticks * 
Cyclospora cayetanensis ** Tunga penetrans **  
Dientamoeba fragilis *** Pediculus humanus capitis *  
Endolimax nana *** Pediculus humanus corporis *  
Entamoeba histolytica **   
Entamoeba dispar ** 
Entamoeba polecki **   
Entamoeba gingivalis *   
Enteromonas hominis **   
Giardia intestinalis ***   
Leishmania tropica **   
Leishmania braziliensis **   
Pentatrichomonas hominis **   
Plasmodium falciparum **   
Plasmodium malariae **   
Plasmodium ovale **   
Plasmodium vivax **   
Toxoplasma gondii *   
Trichomonas vaginalis *   
Trypanosoma cruzi **   
Acanthocephala; Moniliformis 
moniliformis **  ** 
Key to coding: Endemic cases *, Imported cases **, Endemic and imported cases ***. 
In the mid-20th Century, Tasmania experienced one of the highest rates of human hydatid 
disease in the world [47,48]. Echinococcus granulosus, which causes cystic echinococcosis is the only 
member of the genus Echinococcus to be found in Australia. It was introduced during the early period 
of European settlement and described in domestic animals before 1840 [49]. In the early 1960s, the 
state government commenced a hydatid control programme across Tasmania aimed at stopping 
transmission of hydatid disease to humans. By 1996, Tasmania was declared provisionally free of 
hydatids in dogs and livestock [50]. 
Of the helminth cases, the Tasmanian cases of Trichinella pseudospiralis and Haycocknema 
perplexum are the most intriguing as they were the first human cases of these worms ever reported 
[51–53]. It was first described from a patient in Tasmania by Spratt et al. [54]. Subsequent cases 
diagnosed had all lived in or visited Tasmania. Many had histories of contact with native animals or 
eating bush meat and it was thought that the infection was an endemic zoonosis from Tasmania 
[55,56]. A subsequent case from tropical North Queensland had no contact with Tasmania and a re-
evaluation of all the recorded cases showed that they all had contact with the tropical north of 
Australia. The result that the condition was considered to be endemic there and being redescribed 
the disease as “tropical parasitic myositis” [57]. However, the most recently reported case from 
Tasmania had no travel history, except to Melbourne in southern Victoria [56], confirming that H. 
perplexum is indeed endemic to Tasmania. The natural reservoir of H. perplexum has not been found 
to date and the mode of transmission to humans is also unknown. Human T. pseudospiralis has 
subsequently been described from humans in France and Thailand but the enigma of H. perplexum 
continues. 
Vaccine development and application to control zoonotic diseases in food animals, companion 
animals, and wildlife have made a significant impact in reducing the incidence of zoonotic diseases 
in people [58]. At the same time, biosecurity in Australia has played a critical role in maintaining its 
reputation as a country free of severe pests and diseases. The Commonwealth Quarantine Service 
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started operations in 1908 and today Biosecurity Australia monitors plant and animal health across 
Australia. While most infections in Australia have been controlled it has led to over-confidence 
regarding their importance (or even existence) today. Unfortunately, while ubiquitous protozoan 
species have been reported in wildlife across Australia [51–61] the life cycles, ecology, and general 
biology of most parasites of wildlife in Australia are poorly understood. Much of the work to date 
has been opportunistic with unreliable funding opportunities, but with modern methods and ‘omic’ 
technology [62] offering an avenue for major advances in the field, there is potential for renewed 
support and interest. 
An analysis of imported malaria in Tasmania (Table 2) was initially reported over a 5-year period 
from 1987 to 1992 and subsequently extended to cover 1987–1994 [63]. During this period, 80 cases of 
malaria were diagnosed covering three species: Plasmodium vivax (81.2%) followed by Plasmodium 
falciparum (16.2%), and Plasmodium malariae (2.6%). Cases came from Asia, Southeast Asia, Africa, 
Papua New Guinea (PNG), Vanuatu, the Solomons, and one case acquired in Thursday Island 
(administratively a part of Australia and an area considered free from malaria due to control 
measures). The cases were diagnosed from across the State, including two from Antarctica—a region 
administered from Tasmania (Goldsmid, pers. Comm. 2019). These cases continued to influence 
curriculum development in tropical and travel disease in the undergraduate medical school. 
Expanding medical training in tropical disease for Tasmanian medical practitioners was highlighted 
by one of these malaria cases when originally misdiagnosed (as influenza). The general practitioner 
(GP) involved explained the patient presented during an influenza epidemic in his area and, as he 
ruefully admitted, he did not ask the patient about any travel history. Luckily it was a case of benign 
tertian malaria (Plasmodium vivax)—the error could have been tragic if it had been a case of P. 
falciparum malaria 
New treatments are, however, being developed, albeit rather slowly and an example of this is 
the treatment of Plasmodium vivax relapses with tafenoquine (kozenis) and artesunate for severe 
falciparum malaria [64]. The recent and rapid clinical development of vaccines is making 
considerable impact world-wide. The vaccine against Plasmodium falciparum, RTS,S/AS01 (RTS,S)is a 
promising vaccine candidate for malaria currently part of a landmark pilot program in three African 
countries, and is available to children up to 2 years of age [65]. Another recent example is the vesicular 
stomatitis virus-based Ebola virus vaccine (VSV-EBOV) currently in a clinical trial [66]. It is viewed 
as a potential tool for both current and future Ebola outbreaks. 
Infectious diseases and pandemic preparedness remain a priority on the world agenda, despite 
the shift in focus to non-communicable diseases. The Sustainable Development Goals (SDGs) provide 
a framework for a holistic answer to the ensuing challenges and respond to these complex 
interactions but collaboration between research disciplines is essential. A recent paper by committee 
members of the World Heath Summit supports the view that leading institutions and organisations 
are responsible to promote transdisciplinary, cross-sectoral, science-based and concerted efforts for 
more efficient and equitable ways to advance health on a global scale [67]. 
4. Conclusions 
Changing attitudes over the course of several decades mean medicine has slowly been 
considered in global terms rather than discrete specialties. The changing patterns in disease suggest 
a need for new conceptual models in medical training and medical education. There have been many 
attempts to frame the impact of globalisation on health [68] based on international health, public 
health, and tropical medicine [68–70]. During the period of our work in medical curriculum 
development and medical microbiology teaching the commoner categories included: tropical 
medicine, travel medicine, migrant medicine, and traditional and complementary medicine. All of 
these specialties, to varying degrees, can be encompassed under the broad title of ‘Global Medicine’. 
This has coincided with attempts to integrate modern science into the medical curricula and equip 
health professionals to meet the future health needs of populations. 
The One Health concept recognises the health connections between humans, animals, and their 
shared environments [71]. Its approach has been endorsed by a number of medical and public health 
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organisations and medical schools around the world [71]. The concept of planetary health, which 
became part of the fabric of integrative medicine in the 1990s, has since become a concept that has 
penetrated mainstream academic and medical discourse. In fact, it provides a new multidisciplinary 
approach to understanding the interconnections between environmental and human health. It is 
often viewed as a response to existing fields of public health, environmental health, Ecohealth, One 
Health, and international health [72]. 
The impressive range of infections currently seen and potentially emergent emphasises what 
Bradley [73] warned the medical profession over 30 years ago, that a holistic view is one all specialties 
must embrace. Our work in medical education and our past experiences are still valid today. Tropical 
diseases are not confined to the tropics. They are being increasingly encountered in non-tropical areas 
and thus must be considered a global problem. 
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